Description
ARA-290 is a synthetic peptide derived from erythropoietin (EPO), specifically engineered to activate the innate repair receptor (IRR) while avoiding stimulation of the erythropoietin receptor (EPOR) responsible for red blood cell production. This selective mechanism allows ARA-290 to provide powerful tissue-protective, anti-inflammatory, and neuroprotective effects without inducing the hematopoietic side effects typically associated with traditional EPO-based therapies.
Originally developed for its potential in treating complications related to diabetes and neuropathic pain, ARA-290 has demonstrated efficacy in preclinical and early clinical studies for reducing inflammation, promoting vascular repair, and modulating immune responses. Its non-hematopoietic profile makes it an ideal research candidate for addressing a broad range of conditions, including chronic inflammatory diseases, tissue ischemia, and autoimmune disorders.
By mimicking the protective signaling pathways of EPO without affecting red blood cell production, ARA-290 represents a novel class of regenerative peptide therapies focused on promoting healing at the cellular level. All Precision Biocare peptides are compounded in the U.S. and third-party tested to ensure purity and quality for advanced research applications.
Reviews
There are no reviews yet.